Refine
Year of publication
Document Type
- Preprint (795)
- Article (649)
- Conference Proceeding (4)
- Doctoral Thesis (1)
- Working Paper (1)
Language
- English (1443)
- German (6)
- Multiple languages (1)
Has Fulltext
- yes (1450)
Is part of the Bibliography
- no (1450)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- e +-e − Experiments (11)
- BESIII (10)
- LHC (9)
- Branching fraction (7)
- Particle and Resonance Production (7)
- Heavy-ion collision (6)
- HIV (5)
- Spectroscopy (5)
- ALICE experiment (4)
- Charm Physics (4)
- Charm physics (4)
- Collective Flow (4)
- Electroweak interaction (4)
- Inverse kinematics (4)
- Jets (4)
- Lepton colliders (4)
- Quark-Gluon Plasma (4)
- Quarkonium (4)
- Quasi-free scattering (4)
- ALICE (3)
- Biomarkers (3)
- COVID-19 (3)
- Charmed mesons (3)
- Exotics (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Hadronic decays (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Oncology (3)
- Osteoporosis (3)
- Particle and resonance production (3)
- QCD (3)
- Spectroscopic factors (3)
- breast cancer (3)
- e+-e− Experiments (3)
- pp collisions (3)
- Antiretroviral therapy (2)
- Beauty production (2)
- Bone density (2)
- Branching fractions (2)
- CT (2)
- Cirrhosis (2)
- Diagnostic markers (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Epilepsy (2)
- Früherkennung (2)
- Heart failure (2)
- Heavy Quark Production (2)
- Hypertension (2)
- Inflammation (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Leptonic, semileptonic & radiative decays (2)
- Liver diseases (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Nuclear reactions (2)
- Particle Correlations and Fluctuations (2)
- Particle correlations and fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Seizure (2)
- Shell model (2)
- Single electrons (2)
- Single-particle states (2)
- Spine (2)
- biomarker (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- pelvic packing (2)
- reference values (2)
- screening (2)
- 900 GeV (1)
- ABC transporters (1)
- ALICE detector (1)
- ALK (1)
- APRI (1)
- ATPases (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Acute coronary syndrome (1)
- Alpha-synuclein (1)
- Angiography (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Antiviral therapy (1)
- Aortic valve (1)
- Apoptosis (1)
- Artesunate (1)
- Atherosclerosis (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atrial fibrillation (1)
- B cell receptor (1)
- B cell subpopulations (1)
- BESIII detector (1)
- BRCA1 (1)
- BRCA2 (1)
- Bacterial genomics (1)
- Bayesian inference (1)
- Beam loss (1)
- Bhabha (1)
- Biomarker (1)
- Bipolar disorder (1)
- Bleeding (1)
- Blood plasma (1)
- Blood pressure (1)
- Body mass index (1)
- Bone diseases, Metabolic (1)
- Boosted Jets (1)
- Born cross section measurement (1)
- Breast cancer (1)
- C-clamp (1)
- C3M (1)
- C4M (1)
- CD16 (1)
- CD56 (1)
- COVID 19 (1)
- CP violation (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CVID (1)
- Cancer (1)
- Cancer treatment (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardiac troponin (1)
- Cardiology (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell-to-Cell Spread (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Chemoradiotherapy (1)
- Child (1)
- Children (1)
- Chronic obstructive pulmonary disease (1)
- Circular accelerators (1)
- Clinical study (1)
- Clinical variation (1)
- Cohort studies (1)
- Collective Flow, (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Complex II (1)
- Computed tomography, X-ray (1)
- Consensus (1)
- Consensus document (1)
- Contrast agent (1)
- Costs (1)
- Cross section (1)
- Cross sections (1)
- Culture positive (1)
- D meson (1)
- Dark photon (1)
- Dark sector (1)
- De-isolation (1)
- Death rates (1)
- Dermatomyositis (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Digestive system procedures (1)
- Direct nuclear reactions (1)
- Direct reactions (1)
- Docetaxel (1)
- Drug screens (1)
- Dual-energy computed tomography (1)
- Economics (1)
- Eicosanoids (1)
- Ejection fraction (1)
- Elderly (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Elliptic flow (1)
- Endocrinology (1)
- Endoscopy (1)
- Ephrin-B2–EphB4 (1)
- Esophagectomy (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Exercise training (1)
- Exosomes (1)
- FAPI PET (1)
- FIB-4 (1)
- FOS: Physical sciences (1)
- Falciparum (1)
- Fatty acids (1)
- Fatty liver (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- First-line combination antiretroviral therapy (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Forschung (1)
- Frailty (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- General practitioners (1)
- Genetics (1)
- German PID-NET registry (1)
- Gleason Grade Group (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HER2-positive (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health economics (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion storage ring (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematology (1)
- Hepatitis B virus (1)
- Hepatitis C virus (1)
- Hepatocellular carcinoma (1)
- Hepatotoxicity (1)
- Hereditary breast and ovarian cancer (1)
- Herniated disk (1)
- High Energy Physics - Experiment (hep-ex) (1)
- High-energy neutron detection (1)
- Human behaviour (1)
- Hyperons (1)
- ICL (1)
- ICL V4c (1)
- INR (1)
- IgG substitution therapy (1)
- Image processing (1)
- Implantable cardioverter-defibrillator (1)
- In-TIPS thrombosis (1)
- Inclusive branching fraction (1)
- Inclusive spectra (1)
- Initial state radiation (1)
- Intensity interferometry (1)
- International normalized ratio (1)
- Intervertebral disc displacement (1)
- Invariant Mass Distribution (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- Jet Physics (1)
- Jet Substructure (1)
- K0S (1)
- Kidney diseases (1)
- Lehre (1)
- Leukemias (1)
- Liver (1)
- Liver enzymes (1)
- Liver fibrosis (1)
- Liver transplantation (1)
- Long non-coding RNAs (1)
- Low & intermediate-energy accelerators (1)
- MHC (1)
- MRI (1)
- MTOR inhibitor (1)
- MYCN amplification (1)
- Malaria (1)
- Masquelet technique (1)
- Material budget (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Molecular diagnostic testing (1)
- Molecular neuroscience (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-neutron detection (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myocardial infarction (1)
- Myopia (1)
- NK cells (1)
- NMR spectroscopy (1)
- Nanoscale biophysics (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neural network (1)
- Neutrinos (1)
- Non-small cell lung cancer (1)
- Noninferiority (1)
- Nontuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- One-nucleon removal (1)
- Open pulmonary tuberculosis (1)
- Opportunistic infections (1)
- Optical tweezers (1)
- Orbital electron capture (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- PDE‐5‐inhibitor (1)
- PID prevalence (1)
- PYTHIA (1)
- Pacemaker (1)
- Parkinson’s disease (1)
- Particle phenomena (1)
- Pathological complete response (1)
- Pb–Pb (1)
- Percutaneous (1)
- Personalized medicine (1)
- Phakic (1)
- Phantoms (imaging) (1)
- Phospholipids (1)
- Photon counting (1)
- Physical activity (1)
- Plasmodium (1)
- Plastic scintillator array (1)
- Point-of-care testing (1)
- Polarization (1)
- Pre-treatment drug resistance mutations (1)
- Predictive markers (1)
- Prevention (1)
- Production Cross Section (1)
- Prognosis (1)
- Properties of Hadrons (1)
- Protease inhibitor therapy (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- QGP (1)
- Quantitative Imaging (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quinine (1)
- RAS pathway (1)
- Radiative capture (1)
- Radiative decay (1)
- Rapidity Range (1)
- Rare decays (1)
- Reactions with relativistic radioactive beams (1)
- Registries (1)
- Regulatory networks (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research (1)
- Residency (1)
- Resolution Parameter (1)
- Respiratory infections (1)
- Retinal diseases (1)
- Rhabdomyoma (1)
- SARS CoV 2 (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SR-BI (1)
- SVR (1)
- Semi-leptonic decays (1)
- Severe malaria (1)
- Single muons (1)
- Single particle decay spectroscopy (1)
- Sociodemographic characteristics (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Sphingolipids (1)
- Sputum smear-negative (1)
- Stentoplasty (1)
- Storage ring (1)
- Subependymal giant cell astrocytoma (1)
- Super-resolution microscopy (1)
- Surgical oncology (1)
- Systematic Uncertainty (1)
- TB-therapy (1)
- TIPS (1)
- TR (1)
- TSC (1)
- Teaching (1)
- Techniques Electromagnetic calorimeters (1)
- Time Projection Chamber (1)
- Tomography (1)
- Tomography (x-ray computed) (1)
- Tracking (1)
- Transferases (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transverse momentum (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- Two body weak decay (1)
- Type 2 diabetes (1)
- University hospitals (1)
- Universitätskliniken (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- Virological failure (1)
- Virtual noncalcium reconstructions (1)
- Weiterbildung (1)
- X-ray computed (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Y states (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- acute myeloid leukemia (1)
- adaptive immunity (1)
- adult and elderly patients (1)
- allogeneic transplantation (1)
- angiography (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- annual bleeding rate (1)
- anterior chamber depth changes (1)
- antigen presentation (1)
- auditory system (1)
- autoimmunity (1)
- biopsy cores (1)
- bone marrow derived mononuclear cells (1)
- cART (1)
- cancer therapy (1)
- cardiac magnetic resonance (1)
- castration resistance (1)
- cataract surgery (1)
- cell-free protein synthesis (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- children (1)
- chronic kidney disease (1)
- clinical stage (1)
- co-infection (1)
- cohlear implant (1)
- cohort study (1)
- collagen degradation marker (1)
- component study (1)
- computer-assisted (1)
- critical size defect (1)
- cryo-EM (1)
- cyanines (1)
- cytarabine dose (1)
- dE/dx (1)
- decision aids (1)
- detector (1)
- dimuon (1)
- dislocation (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- e-scooter (1)
- effective lens position (1)
- effectiveness (1)
- elderly (1)
- electric and acustic stymulation (1)
- electric scooter (1)
- electron-positron collision (1)
- embolization (1)
- erectile dysfunction (1)
- experimental results (1)
- exponential model (1)
- external fixation (1)
- fibrosis imaging (1)
- fibrotest (1)
- flow cytometry (1)
- fracture (1)
- hadron spectroscopy (1)
- hadronic events (1)
- haemophilia A (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- heavy-ion storage rings (1)
- helicity amplitude analysis (1)
- hemodynamic instability (1)
- hemorrhage (1)
- hepatitis C (1)
- high-risk neuroblastoma (1)
- immune reconstitution (1)
- inclusive J/ψ decays (1)
- induced membrane (1)
- interoperability (1)
- intrinsically disordered region (1)
- inverse kinematics (1)
- lactate (1)
- lapatinib (1)
- learning loss (1)
- lung cancer (1)
- mTOR inhibitor (1)
- management (1)
- membrane proteins (1)
- metastasis (1)
- metastatic prostate cancer (1)
- mindfulness (1)
- molecular machines (1)
- molecular tug-of-war (1)
- mortality (1)
- myocardial fibrosis (1)
- neoadjuvant therapy (1)
- neutron-induced reactions (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-invasive fibrosis assessment (1)
- nonstructural proteins (1)
- non‐selective beta‐blocker (1)
- nuclear cardiology (1)
- number of J/ψ events (1)
- oxLDL (1)
- p53 pathway (1)
- pIOL (1)
- pelvic injury (1)
- pelvic ring fracture (1)
- peptide editing (1)
- peptide-loading complex (1)
- photoacid (1)
- phylogeny (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- point shear wave elastography (1)
- portal hypertension (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- proteomics (1)
- proton transfer (1)
- pseudoexfoliative syndrome (1)
- psychotherapy process (1)
- quality control (1)
- quark gluon plasma (1)
- randomized controlled trial (RCT) (1)
- registry for primary immunodeficiency (1)
- resectability (1)
- risk group (1)
- scaffold size (1)
- scar (1)
- school closure (1)
- seed and soil (1)
- sequence alignment (1)
- smart home (1)
- smart living (1)
- spectra (1)
- sphingolipid (1)
- spinal bone metastasis (1)
- spine (1)
- spiro compounds (1)
- stage migration (1)
- structural biology (1)
- structural proteins (1)
- student achievement (1)
- surrogate reactions (1)
- survival (1)
- systematic review (1)
- tapasin (1)
- tetraquark (1)
- therapeutic alliance (1)
- traffic accident (1)
- transient elastography (1)
- transportation (1)
- trastuzumab (1)
- traumatic brain injury (1)
- trigger efficiency (1)
- ultrafast spectroscopy (1)
- vertebroplasty (1)
- web of things (1)
- x-ray techniques (1)
- Λ+c baryon (1)
- Σ hyperon (1)
- ψ(3686) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1314)
- Frankfurt Institute for Advanced Studies (FIAS) (960)
- Informatik (925)
- Medizin (104)
- ELEMENTS (18)
- Geowissenschaften (10)
- Biochemie und Chemie (5)
- Exzellenzcluster Herz-Lungen-System (3)
- Informatik und Mathematik (3)
- Biochemie, Chemie und Pharmazie (2)
The 124Xe(p,γ) reaction has been measured for the first time at energies around the Gamow window by using stored ions at the ESR facility. The desired beam energies below 10 MeV/u introduce new experimental challenges like windowless ions detection under UHV conditions, extremely short beam lifetimes and efficient beam deceleration and cooling, all of which have been successfully met.
Hintergrund: Ab Frühjahr 2020 kam es zur weltweiten Verbreitung von SARS-CoV‑2 mit der heute als erste Welle der Pandemie bezeichneten Phase ab März 2020. Diese resultierte an vielen Kliniken in Umstrukturierungen und Ressourcenverschiebungen. Ziel unserer Arbeit war die Erfassung der Auswirkungen der Pandemie auf die universitäre Hals-Nasen-Ohren(HNO)-Heilkunde für die Forschung, Lehre und Weiterbildung. Material und Methoden: Die Direktorinnen und Direktoren der 39 Universitäts-HNO-Kliniken in Deutschland wurden mithilfe einer strukturierten Online-Befragung zu den Auswirkungen der Pandemie im Zeitraum von März bis April 2020 auf die Forschung, Lehre und die Weiterbildung befragt. Ergebnisse: Alle 39 Direktorinnen und Direktoren beteiligten sich an der Umfrage. Hiervon gaben 74,4 % (29/39) an, dass es zu einer Verschlechterung ihrer Forschungstätigkeit infolge der Pandemie gekommen sei. Von 61,5 % (24/39) wurde berichtet, dass pandemiebezogene Forschungsaspekte aufgegriffen wurden. Von allen Kliniken wurde eine Einschränkung der Präsenzlehre berichtet und 97,5 % (38/39) führten neue digitale Lehrformate ein. Im Beobachtungszeitraum sahen 74,4 % der Klinikdirektoren die Weiterbildung der Assistenten nicht gefährdet. Schlussfolgerung: Die Ergebnisse geben einen Einblick in die heterogenen Auswirkungen der Pandemie. Die kurzfristige Bearbeitung pandemiebezogener Forschungsthemen und die Einführung innovativer digitaler Konzepte für die studentische Lehre belegt eindrücklich das große innovative Potenzial und die schnelle Reaktionsfähigkeit der HNO-Universitätskliniken, um auch während der Pandemie ihre Aufgaben in der Forschung, Lehre und Weiterbildung bestmöglich zu erfüllen.
Poster presentation: Purpose of the study The aim of the Rainbow Cohort is to assess the tolerability and efficacy of initiating treatment with, or switching treatment to the saquinavir (SQV) 500 mg film-coated tablet formulation. We present the final 48-week subgroup analysis of PI-experienced, but SQV-naïve patients. ...
Poster presentation: Purpose of the study The aim of the Rainbow Cohort is to assess the tolerability and efficacy of initiating treatment with, or switching treatment to saquinavir (SQV) 500 mg film-coated tablet formulation. We present the final 48-week subgroup analysis of antiretroviral therapy (ART)-naïve patients. ...
Objectives: An increasing number of treatment-determining biomarkers has been identified in non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable optimal individualized treatment. However, data on implementation of these recommendations in the “real-world” setting are scarce. This study presents comprehensive details on the frequency, methodology and results of biomarker testing of advanced NSCLC in Germany.
Patients and methods: This analysis included 3,717 patients with advanced NSCLC (2,921 non-squamous; 796 squamous), recruited into the CRISP registry at start of systemic therapy by 150 German sites between December 2015 and June 2019. Evaluated were the molecular biomarkers EGFR, ALK, ROS1, BRAF, KRAS, MET, TP53, RET, HER2, as well as expression of PD-L1.
Results: In total, 90.5 % of the patients were tested for biomarkers. Testing rates were 92.2 % (non-squamous), 70.7 % (squamous) and increased from 83.2 % in 2015/16 to 94.2% in 2019. Overall testing rates for EGFR, ALK, ROS1, and BRAF were 72.5 %, 74.5 %, 66.1 %, and 53.0 %, respectively (non-squamous). Testing rates for PD-L1 expression were 64.5 % (non-squamous), and 58.5 % (squamous). The most common testing methods were immunohistochemistry (68.5 % non-squamous, 58.3 % squamous), and next-generation sequencing (38.7 % non-squamous, 14.4 % squamous). Reasons for not testing were insufficient tumor material or lack of guideline recommendations (squamous). No alteration was found in 37.8 % (non-squamous), and 57.9 % (squamous), respectively. Most common alterations in non-squamous tumors (all patients/all patients tested for the respective biomarker): KRAS (17.3 %/39.2 %), TP53 (14.1 %/51.4 %), and EGFR (11.0 %/15.1 %); in squamous tumors: TP53 (7.0 %/69.1 %), MET (1.5 %/11.1 %), and EGFR (1.1 %/4.4 %). Median PFS (non-squamous) was 8.7 months (95 % CI 7.4–10.4) with druggable EGFR mutation, and 8.0 months (95 % CI 3.9–9.2) with druggable ALK alterations.
Conclusion: Testing rates in Germany are high nationwide and acceptable in international comparison, but still leave out a significant portion of patients, who could potentially benefit. Thus, specific measures are needed to increase implementation.
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
Background: Patients with chronic kidney disease (CKD) are at high risk of myocardial infarction. Cardiac troponins are the biomarkers of choice for the diagnosis of acute myocardial infarction (AMI) without ST‐segment elevation (NSTE). In patients with CKD, troponin levels are often chronically elevated, which reduces their diagnostic utility when NSTE‐AMI is suspected. The aim of this study was to derive a diagnostic algorithm for serial troponin measurements in patients with CKD and suspected NSTE‐AMI.
Methods and Results: Two cohorts, 1494 patients from a prospective cohort study with high‐sensitivity troponin I (hs‐cTnI) measurements and 7059 cases from a clinical registry with high‐sensitivity troponin T (hs‐cTnT ) measurements, were analyzed. The prospective cohort comprised 280 CKD patients (estimated glomerular filtration rate <60 mL/min/1.73 m2). The registry data set contained 1581 CKD patients. In both cohorts, CKD patients were more likely to have adjudicated NSTE‐AMI than non‐CKD patients. The specificities of hs‐cTnI and hs‐cTnT to detect NSTE‐AMI were reduced with CKD (0.82 versus 0.91 for hs‐cTnI and 0.26 versus 0.73 for hs‐cTnT) but could be restored by applying optimized cutoffs to either the first or a second measurement after 3 hours. The best diagnostic performance was achieved with an algorithm that incorporates serial measurements and rules in or out AMI in 69% (hs‐cTnI) and 55% (hs‐cTnT) of CKD patients.
Conclusions: The diagnostic performance of high‐sensitivity cardiac troponins in patients with CKD with suspected NSTE‐AMI is improved by use of an algorithm based on admission troponin and dynamic changes in troponin concentration.
Background: Treatment of patients presenting with possible acute myocardial infarction (AMI) is based on timely diagnosis and proper risk stratification aided by biomarkers. We aimed at evaluating the predictive value of GDF-15 in patients presenting with symptoms suggestive of AMI.
Methods: Consecutive patients presenting with suspected AMI were enrolled in three study centers. Cardiovascular events were assessed during a follow-up period of 6 months with a combined endpoint of death or MI.
Results: From the 1818 enrolled patients (m/f = 1208/610), 413 (22.7%) had an acute MI and 63 patients reached the combined endpoint. Patients with MI and patients with adverse outcome had higher GDF-15 levels compared with non-MI patients (967.1pg/mL vs. 692.2 pg/L, p<0.001) and with event-free patients (1660 pg/mL vs. 756.6 pg/L, p<0.001). GDF-15 levels were lower in patients with SYNTAX score ≤ 22 (797.3 pg/mL vs. 947.2 pg/L, p = 0.036). Increased GDF-15 levels on admission were associated with a hazard ratio of 2.1 for death or MI (95%CI: 1.67–2.65, p<0.001) in a model adjusted for age and sex and of 1.57 (1.13–2.19, p = 0.008) adjusted for the GRACE score variables. GDF-15 showed a relevant reclassification with regards to the GRACE score with an overall net reclassification index (NRI) of 12.5% and an integrated discrimination improvement (IDI) of 14.56% (p = 0.006).
Conclusion: GDF-15 is an independent predictor of future cardiovascular events in patients presenting with suspected MI. GDF-15 levels correlate with the severity of CAD and can identify and risk-stratify patients who need coronary revascularization.
Background: The introduction of modern troponin assays has facilitated diagnosis of acute myocardial infarction due to improved sensitivity with corresponding loss of specificity. Atrial fibrillation (AF) is associated with elevated levels of troponin. The aim of the present study was to evaluate the diagnostic performance of troponin I in patients with suspected acute coronary syndrome and chronic AF.
Methods: Contemporary sensitive troponin I was assayed in a derivation cohort of 90 patients with suspected acute coronary syndrome and chronic AF to establish diagnostic cut-offs. These thresholds were validated in an independent cohort of 314 patients with suspected myocardial infarction and AF upon presentation. Additionally, changes in troponin I concentration within 3 hours were used.
Results: In the derivation cohort, optimized thresholds with respect to a rule-out strategy with high sensitivity and a rule-in strategy with high specificity were established. In the validation cohort, application of the rule-out cut-off led to a negative predictive value of 97 %. The rule-in cut-off was associated with a positive predictive value of 88 % compared with 71 % if using the 99th percentile cut-off. In patients with troponin I levels above the specificity-optimized threshold, additional use of the 3-hour change in absolute/relative concentration resulted in a further improved positive predictive value of 96 %/100 %.
Conclusions: Troponin I concentration and the 3-hour change in its concentration provide valid diagnostic information in patients with suspected myocardial infarction and chronic AF. With regard to AF-associated elevation of troponin levels, application of diagnostic cut-offs other than the 99th percentile might be beneficial.
We report a measurement of the observed cross sections of e+ e− → J/ψX based on 3.21 fb − 1 of data accumulated at energies from 3.645 to 3.891 GeV with the BESIII detector operated at the BEPCII collider. In analysis of the cross sections, we measured the decay branching fractions of B(ψ(3686) → J/ψX) = (64.4 ± 0.6 ± 1.6)% and B(ψ(3770) → J/ψX) = (0.5 ± 0.2 ± 0.1)% for the first time. The energy-dependent line shape of these cross sections cannot be well described by two Breit-Wigner (BW) amplitudes of the expected decays ψ (3686) → J/ψX and ψ(3770) → J/ψX. Instead, it can be better described with one more BW amplitude of the decay R(3760)→ J/ψX. Under this assumption, we extracted the R (3760) mass M R (3760 ) = 3766.2 ± 3.8 ± 0.4 MeV/c2, total width Γ tot R ( 3760 ) = 22.2 ± 5.9 ± 1.4 MeV, and product of leptonic width and decay branching fraction
ΓeeR(3760) B[R(3760) → J/ψX] = (79.4 ± 85.5 ± 11.7) eV. The significance of the R(3760) is 5.3σ. The first uncertainties of these measured quantities are from fits to the cross sections and second systematic.
Comparative proteomics reveals a diagnostic signature for pulmonary head‐and‐neck cancer metastasis
(2018)
Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during the course of their disease. Despite the clinical importance of discrimination, reliable diagnostic biomarkers are still lacking. Here, we have characterised a cohort of squamous cell lung (SQCLC) and head‐and‐neck (HNSCC) carcinomas by quantitative proteomics. In a training cohort, we quantified 4,957 proteins in 44 SQCLC and 30 HNSCC tumours. A total of 518 proteins were found to be differentially expressed between SQCLC and HNSCC, and some of these were identified as genetic dependencies in either of the two tumour types. Using supervised machine learning, we inferred a proteomic signature for the classification of squamous cell carcinomas as either SQCLC or HNSCC, with diagnostic accuracies of 90.5% and 86.8% in cross‐ and independent validations, respectively. Furthermore, application of this signature to a cohort of pulmonary squamous cell carcinomas of unknown origin leads to a significant prognostic separation. This study not only provides a diagnostic proteomic signature for classification of secondary lung tumours in HNSCC patients, but also represents a proteomic resource for HNSCC and SQCLC.
Calibration of TCCON column-averaged CO₂: the first aircraft campaign over European TCCON sites
(2011)
The Total Carbon Column Observing Network (TCCON) is a ground-based network of Fourier Transform Spectrometer (FTS) sites around the globe, where the column abundances of CO2, CH4, N2O, CO and O2 are measured. CO2 is constrained with a precision better than 0.25% (1-σ). To achieve a similarly high accuracy, calibration to World Meteorological Organization (WMO) standards is required. This paper introduces the first aircraft calibration campaign of five European TCCON sites and a mobile FTS instrument. A series of WMO standards in-situ profiles were obtained over European TCCON sites via aircraft and compared with retrievals of CO2 column amounts from the TCCON instruments. The results of the campaign show that the FTS measurements are consistently biased 1.1% ± 0.2% low with respect to WMO standards, in agreement with previous TCCON calibration campaigns. The standard a priori profile for the TCCON FTS retrievals is shown to not add a bias. The same calibration factor is generated using aircraft profiles as a priori and with the TCCON standard a priori. With a calibration to WMO standards, the highly precise TCCON CO2 measurements of total column concentrations provide a suitable database for the calibration and validation of nadir-viewing satellites
Calibration of TCCON column-averaged CO₂: the first aircraft campaign over European TCCON sites
(2011)
The Total Carbon Column Observing Network (TCCON) is a ground-based network of Fourier Transform Spectrometer (FTS) sites around the globe, where the column abundances of CO2, CH4, N2O, CO and O2 are measured. CO2 is constrained with a precision better than 0.25 %. To achieve a similarly high accuracy, calibration to World Meteorological Organization (WMO) standards is required. This paper introduces the first aircraft calibration campaign of five European TCCON sites and a mobile FTS instrument. A series of WMO standards in-situ profiles were obtained over European TCCON sites via aircraft and compared with retrievals of CO2 column amounts from the TCCON instruments. The results of the campaign show that the FTS measurements are consistently biased 1.0 % ± 0.2 % low with respect to WMO standards, in agreement with previous TCCON calibration campaigns. The standard a priori profile for the TCCON FTS retrievals is shown to not add a bias. The same calibration factor is generated using aircraft profiles as a priori and with the TCCON standard a priori. With a calibration to WMO standards, the highly precise TCCON CO2 measurements of total column concentrations provide a suitable database for the calibration and validation of nadir-viewing satellites.
Using 2.93 fb−1 of 𝑒+𝑒− collision data taken at a center-of-mass energy of 3.773 GeV with the BESIII detector, we report the first measurements of the absolute branching fractions of 14 hadronic 𝐷0(+) decays to exclusive final states with an 𝜂, e.g., 𝐷0→𝐾−𝜋+𝜂, 𝐾0𝑆𝜋0𝜂, 𝐾+𝐾−𝜂, 𝐾0𝑆𝐾0𝑆𝜂, 𝐾−𝜋+𝜋0𝜂, 𝐾0𝑆𝜋+𝜋−𝜂, 𝐾0𝑆𝜋0𝜋0𝜂, and 𝜋+𝜋−𝜋0𝜂; 𝐷+→𝐾0𝑆𝜋+𝜂, 𝐾0𝑆𝐾+𝜂, 𝐾−𝜋+𝜋+𝜂, 𝐾0𝑆𝜋+𝜋0𝜂, 𝜋+𝜋+𝜋−𝜂, and 𝜋+𝜋0𝜋0𝜂. Among these decays, the 𝐷0→𝐾−𝜋+𝜂 and 𝐷+→𝐾0 𝑆𝜋+𝜂 decays have the largest branching fractions, which are ℬ(𝐷0→𝐾−𝜋+𝜂) = (1.853±0.025stat±0.031syst)% and ℬ(𝐷+→𝐾0𝑆𝜋+𝜂) = (1.309±0.037stat±0.031syst)%, respectively. The charge-parity asymmetries for the six decays with highest event yields are determined, and no statistically significant charge-parity violation is found.
Cross sections of the process 𝑒+𝑒−→𝜋0𝜋0𝐽/𝜓 at center-of-mass energies between 3.808 and 4.600 GeV are measured with high precision by using 12.4 fb−1 of data samples collected with the BESIII detector operating at the BEPCII collider facility. A fit to the measured energy-dependent cross sections confirms the existence of the charmoniumlike state 𝑌(4220). The mass and width of the 𝑌(4220) are determined to be (4220.4±2.4±2.3) MeV/𝑐2 and (46.2±4.7±2.1) MeV, respectively, where the first uncertainties are statistical and the second systematic. The mass and width are consistent with those measured in the process 𝑒+𝑒−→𝜋+𝜋−𝐽/𝜓. The neutral charmonium-like state 𝑍𝑐(3900)0 is observed prominently in the 𝜋0𝐽/𝜓 invariant-mass spectrum, and, for the first time, an amplitude analysis is performed to study its properties. The spin-parity of 𝑍𝑐(3900)0 is determined to be 𝐽𝑃=1+, and the pole position is (3893.1±2.2±3.0)−𝑖(22.2±2.6±7.0) MeV/𝑐2, which is consistent with previous studies of electrically charged 𝑍𝑐(3900)±. In addition, cross sections of 𝑒+𝑒− → 𝜋0𝑍𝑐(3900)0 → 𝜋0𝜋0𝐽/𝜓 are extracted, and the corresponding line shape is found to agree with that of the 𝑌(4220).
The process 𝑒+𝑒−→𝜙𝜂′ has been studied for the first time in detail using data sample collected with the BESIII detector at the BEPCII collider at center of mass energies from 2.05 to 3.08 GeV. A resonance with quantum numbers 𝐽𝑃𝐶=1−− is observed with mass 𝑀=(2177.5±4.8(stat)±19.5(syst))MeV/𝑐2 and width Γ=(149.0±15.6(stat)±8.9(syst)) MeV with a statistical significance larger than 10𝜎, including systematic uncertainties. If the observed structure is identified with the 𝜙(2170), then the ratio of partial width between the 𝜙𝜂′ by BESIII and 𝜙𝜂 by BABAR is (ℬ𝑅𝜙𝜂Γ𝑅𝑒𝑒)/(ℬ𝑅𝜙𝜂′Γ𝑅𝑒𝑒)=0.23±0.10(stat)±0.18(syst), which is smaller than the prediction of the 𝑠¯𝑠𝑔 hybrid models by several orders of magnitude.
By analyzing a data sample corresponding to an integrated luminosity of 2.93 fb−1 collected at a center-of-mass energy of 3.773 GeV with By analyzing a data sample corresponding to an integrated luminosity of 2.93 fb−1 collected at a center-of-mass energy of 3.773 GeV with the BESIII detector, we measure for the first time the absolute branching fraction of the 𝐷+→𝜂𝜇+𝜈𝜇 decay to be ℬ𝐷+→𝜂𝜇+𝜈𝜇=(10.4±1.0stat±0.5syst)×10−4. Using the world averaged value of ℬ𝐷+→𝜂𝑒+𝜈𝑒, the ratio of the two branching fractions is determined to be ℬ𝐷+→𝜂𝜇+𝜈𝜇/ℬ𝐷+→𝜂𝑒+𝜈𝑒=0.91±0.13(stat+syst), which agrees with the theoretical expectation of lepton flavor universality within uncertainty. By studying the differential decay rates in five four-momentum transfer intervals, we obtain the product of the hadronic form factor 𝑓𝜂+(0) and the 𝑐→𝑑 Cabibbo-Kobayashi-Maskawa matrix element |𝑉𝑐𝑑| to be 𝑓𝜂+(0)|𝑉𝑐𝑑|=0.087±0.008stat±0.002syst. Taking the input of |𝑉𝑐𝑑| from the global fit in the standard model, we determine 𝑓𝜂+(0)=0.39±0.04stat±0.01syst. On the other hand, using the value of 𝑓𝜂+(0) calculated in theory, we find |𝑉𝑐𝑑| = 0.242±0.022stat±0.006syst±0.033theory.
We report the first observation of the semimuonic decay 𝐷+→𝜔𝜇+𝜈𝜇 using an 𝑒+𝑒− collision data sample corresponding to an integrated luminosity of 2.93 fb−1 collected with the BESIII detector at a center-of-mass energy of 3.773 GeV. The absolute branching fraction of the 𝐷+→𝜔𝜇+𝜈𝜇 decay is measured to be ℬ𝐷+→𝜔𝜇+𝜈𝜇=(17.7±1.8stat±1.1syst)×10−4. Its ratio with the world average value of the branching fraction of the 𝐷+→𝜔𝑒+𝜈𝑒 decay probes lepton flavor universality and it is determined to be ℬ𝐷+→𝜔𝜇+𝜈𝜇/ℬPDG 𝐷+→𝜔𝑒+𝜈𝑒=1.05±0.14, in agreement with the standard model expectation within one standard deviation.
We measure the Born cross sections of the process 𝑒+𝑒−→𝐾+𝐾−𝐾+𝐾− at center-of-mass (c.m.) energies, √𝑠, between 2.100 and 3.080 GeV. The data were collected using the BESIII detector at the BEPCII collider. An enhancement at √𝑠=2.232 GeV is observed, very close to the 𝑒+𝑒−→Λ¯Λ production threshold. A similar enhancement at the same c.m. energy is observed in the 𝑒+𝑒−→𝜙𝐾+𝐾− cross section. The energy dependence of the 𝐾+𝐾−𝐾+𝐾− and 𝜙𝐾+𝐾− cross sections differs significantly from that of 𝑒+𝑒−→𝜙𝜋+𝜋−.